Open AccessKMT2C promoter methylation in plasma‐circulating tumor DNA is a prognostic biomarker in non‐small cell lung cancer
Author(s) -
Mastoraki Sofia,
Balgkouranidou Ioanna,
Tsaroucha Emily,
Klinakis Apostolos,
Georgoulias Vassilis,
Lianidou Evi
Publication year - 2021
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12848
Subject(s) - methylation , dna methylation , cancer research , lung cancer , methyltransferase , epigenetics , biomarker , cancer , biology , oncology , microbiology and biotechnology , medicine , gene , gene expression , genetics
Liquid biopsies are emerging noninvasive diagnostic tools in cancer. MLL3 histone methyltransferase is a transcriptional regulator encoded by the tumor suppressor KMT2C gene. We evaluated the prognostic significance of KMT2C epigenetic changes in plasma of NSCLC patients. The detection of KMT2C promoter methylation in cfDNA predicts poor outcomes in NSCLC and merits further evaluation as a circulating epigenetic biomarker.